skip to content »

Dan L. Duncan Cancer Center

Houston, Texas

BCM has 25 departments and more than 90 research and patient-care centers.
Dan L. Duncan Cancer Center
not shown on screen

Chad J. Creighton, Ph.D. - Biostatistician

Associate Professor of Medicine, Baylor College of Medicine

Dr. Chad CreightonPhone: 713-798-2264
Fax: 713-798-2716


1992-1996 - B.S. Physics, University of Idaho
2001-2006 - Ph.D. Bioinformatics, University of Michigan


My focus is on bioinformatics analysis of molecular profiling data, which may include gene expression, microRNA expression, DNA methylation, or DNA copy number. Fundamentally, my work seeks to obtain meaningful information from large scale molecular datasets on questions relevant to improving cancer diagnosis and treatment. This often involves integration of molecular profiling results from different sources. Among other things, I participate extensively in The Cancer Genome Atlas (TCGA) consortium, a large-scale effort to systematically characterize the genomic changes that occur in cancer.

Metabolic pathway deregulation in aggressive kidney cancer (Nature 499:43-9,2013, with Chris Ricketts and W. Marston Linehan)


Current list on PubMed includes the following:

1. The Cancer Genome Atlas Network (including Creighton CJ). “Comprehensive molecular characterization of clear cell renal cell carcinoma.” Nature. 499(7456):43-9, 2013. (PMID:23792563) (Project-wide Analysis Coordinator and Manuscript Coordinator. Contributed main Figures 5 and 3d.)

2. Creighton CJ. “Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors.” PLOS One. In press. (Third place entry in the 2012 NCI-DREAM Drug Sensitivity Prediction Challenge, Sub-challenge 1.)

3. Creighton CJ, Gibbons DL, Kurie JM. “The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective.” Cancer Manag Res. 5:187–195, 2013. (PMID:23986650)

4. Creighton CJ. “The molecular profile of Luminal B breast cancer.” Biologics. 2012(6): 289–297, 2012. (PMID:22956860)

5. The Cancer Genome Atlas Network (including Creighton CJ). “Comprehensive molecular portraits of human breast tumors.” Nature. Nature. 490(7418):61-70, 2012. (PMID:23000897) (contributed main Figures 3 and 5B and Supplemental Figures 1-3)

6. The Cancer Genome Atlas Network (including Creighton CJ). “Comprehensive genomic characterization of squamous cell lung cancers.” Nature. 489(7417):519-25, 2012. (PMID:22960745) (member of writing committee)

7. Donehower LA*, Creighton CJ*, Schultz N, Shinbrot E, Chang K, Gunaratne PH, Muzny D, Sander C, Hamilton SR, Gibbs RA,Wheeler D. “MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.” J Path. 229(1):99-110, 2013. (* = equal contributors) (PMID:22899370)

8. Cancer Genome Atlas Network (including Creighton CJ). “Comprehensive molecular characterization of human colon and rectal cancer.” Nature. 18;487(7407):330-7, 2012. (PMID:22810696)

9. Creighton CJ. “Using large-scale molecular datasets to improve breast cancer treatment.” Breast Cancer Management. 1(1):57-64, 2012.

10. Creighton CJ*, Hernandez-Herrera A*, Jacobsen A*, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, Gibbs RA, Sander C, Hayes DN, Gunaratne PH, The Cancer Genome Atlas Research Network. “Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.” PLoS One. 7(3):e34546, 2012. (* = equal contributors) (PMID:22479643).

11. The Cancer Genome Atlas Research Network (including Creighton CJ). “Integrated genomic analyses of ovarian carcinoma.” Nature. 29;474:609-15, 2011. (PMID: 21720365) (contributed main figures 2b and 2c)

12. Creighton CJ*, Fu X*, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. “Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer.” Breast Cancer Res 12(3):40, 2010. (* = equal contributors) (PMID: 20569503)

13. Creighton CJ*, Benham AL*, Zhu H*, Khan MF, Reid JG, Nagaraja AK, Fountain MD, Dziadek O, Han D, Ma L, Kim J, Hawkins SM, Anderson ML, Matzuk MM, Gunaratne PH. “Discovery of novel microRNAs in female reproductive tract using Next Generation Sequencing.“ PLOS One. 5(3):e9637, 2010. (* = equal contributors) (PMID: 20224791)

14. Creighton CJ*, Fountain MD*, Yu Z*, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, Anderson ML. “Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.” Cancer Res. 70(5):1906-15, 2010. (* = equal contributors) (PMID: 20179198)

15. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. “Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.” Proc Natl Acad Sci U S A. 106(33):13820-5, 2009. (PMID: 19666588)

16. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Schiff R. “Development of resistance to targeted therapies transforms the clinically-associated molecular profile subtype of breast tumor xenografts.” Cancer Res. 68(18):7493-501, 2008. (PMID: 18794137)

17. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, and Lee AV. “Insulin-like growth factor I (IGF-I) activates gene transcription programs strongly associated with poor breast cancer prognosis.” J Clin Oncol. 26(25):4078-85, 2008. (PMID: 18757322)

E-mail this page to a friend